Neurocrine Biosciences's Schizophrenia Treatment Misses Endpoint

Dow Jones09-13

By Connor Hart

Neurocrine Biosciences said its trial of luvadaxistat as a potential treatment to improve cognitive impairment in patients with schizophrenia failed to meet its primary endpoint.

The San Diego biopharmaceutical company said Thursday that a recent study failed to replicate the cognitive endpoints data observed in an earlier study, due in part to the large variability seen in the cognitive measures across the population studied, as well as a potential imbalance in the baseline characteristics of subjects.

Chief Medical Officer Eiry Roberts said the company, as a result, plans to halt further development of luvadaxistat and switch focus to a different potential treatment for schizophrenia, as well as a potential treatment for major depressive disorder.

Shares were down 2.3% to $118.50 in after-hours trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

September 12, 2024 16:33 ET (20:33 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467739969?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-13 04:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467739969","market":"hk","top_or_hot":-1,"title":"Neurocrine Biosciences's Schizophrenia Treatment Misses Endpoint","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Neurocrine Biosciences said its trial of luvadaxistat as a potential treatment to improve cognitive impairment in patients with schizophrenia failed to meet its primary endpoint. \n</p>\n<p>\n  The San Diego biopharmaceutical company said Thursday that a recent study failed to replicate the cognitive endpoints data observed in an earlier study, due in part to the large variability seen in the cognitive measures across the population studied, as well as a potential imbalance in the baseline characteristics of subjects. \n</p>\n<p>\n  Chief Medical Officer Eiry Roberts said the company, as a result, plans to halt further development of luvadaxistat and switch focus to a different potential treatment for schizophrenia, as well as a potential treatment for major depressive disorder. \n</p>\n<p>\n  Shares were down 2.3% to $118.50 in after-hours trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 12, 2024 16:33 ET (20:33 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine Biosciences's Schizophrenia Treatment Misses Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine Biosciences's Schizophrenia Treatment Misses Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-13 04:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Connor Hart \n\n\n \n\n\n  Neurocrine Biosciences said its trial of luvadaxistat as a potential treatment to improve cognitive impairment in patients with schizophrenia failed to meet its primary ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065169927.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2467739969","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467739969","pubTimestamp":1726173180,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Neurocrine Biosciences said its trial of luvadaxistat as a potential treatment to improve cognitive impairment in patients with schizophrenia failed to meet its primary endpoint.The San Diego biopharmaceutical company said Thursday that a recent study failed to replicate the cognitive endpoints data observed in an earlier study, due in part to the large variability seen in the cognitive measures across the population studied, as well as a potential imbalance in the baseline characteristics of subjects.Chief Medical Officer Eiry Roberts said the company, as a result, plans to halt further development of luvadaxistat and switch focus to a different potential treatment for schizophrenia, as well as a potential treatment for major depressive disorder.Shares were down 2.3% to $118.50 in after-hours trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","NBIX":"神经分泌生物科学","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC"},"translate_title":"Neurocrine Biosciences的精神分裂症治疗未达到终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1},"content_text":"By Connor Hart \n\n\n \n\n\n  Neurocrine Biosciences said its trial of luvadaxistat as a potential treatment to improve cognitive impairment in patients with schizophrenia failed to meet its primary endpoint. \n\n\n  The San Diego biopharmaceutical company said Thursday that a recent study failed to replicate the cognitive endpoints data observed in an earlier study, due in part to the large variability seen in the cognitive measures across the population studied, as well as a potential imbalance in the baseline characteristics of subjects. \n\n\n  Chief Medical Officer Eiry Roberts said the company, as a result, plans to halt further development of luvadaxistat and switch focus to a different potential treatment for schizophrenia, as well as a potential treatment for major depressive disorder. \n\n\n  Shares were down 2.3% to $118.50 in after-hours trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 12, 2024 16:33 ET (20:33 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467739969"}